ECT-001-CB
Phase 2Biologic
ECT-001-CB is one of 11 biologic programs targeting MPR. It is currently in Phase 2.
1
Indications
4
Total Trials
1
Active Trials
10
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
17 competitors in MPR
#DrugCompanyPhaseTrials
1Revia
TevaPhase 3
Lioresal
NovartisPhase 3
Glucophage
EMD SeronoPhase 3
Cytosar
TevaPhase 2
Rapamycin
MMaastricht Radiation Oncology
Phase 3
Glycerin
CCalm Water Therapeutics LLC
Phase 3
Ampyra
MMerz North America, Inc.
Phase 1
Fragmin
PfizerPreclinical
Agenerase
GGlaxo Dba Glaxosmithkline
Preclinical
ECT-001-CB
EExCellThera inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
MPR1 trial
Myeloid Malignancies1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ECT-001-CB. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- EExCellThera inc.